Thread by @EBNEO

First up in: "Pharmacotherapy for BPD: We Know Less than We Think We Do" at #HotTopicsNeo2020 is Dr. Gerri Baer (@thegerribaer), Team Leader for Neonatology @US_FDA, discussing "Challenges in Studying Drugs for BPD"
@HotTopicsNeo #neoEBM

Baer: no (zero, zilch, none!) drugs approved in the USA to prevent or treat BPD.

Highlights various cohorts demonstrating the ongoing high burden of BPD:

#HotTopicsNeo2020 @HotTopicsNeo

Baer: broad view of challenges to BPD Rx, illustrated by 3 buckets: understanding phenotypes/endotypes, definitions and classification and choosing adequate endpoints.
#HotTopicsNeo2020 @HotTopicsNeo

Baer: some of the many challenges to developing effective therapies for BPD; phenotypic/endotypic heterogeneity, therapy-based BPD definitions, genetic heterogeneity, focus on short-term, in-hospital effects.

#HotTopicsNeo2020 @HotTopicsNeo

Baer: dream scenario - identify early markers of specific BPD endotypes allowing targeted therapy that decreases burden on clinically meaningful endpoints.

#HotTopicsNeo2020 @HotTopicsNeo